Zymeworks Q4 Earnings Call Highlights [Yahoo! Finance]
Zymeworks Inc. (ZYME)
Last zymeworks inc. earnings: 3/2 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.zymeworks.com/overview
Company Research
Source: Yahoo! Finance
Zymeworks (NASDAQ:ZYME) executives used the company's fourth-quarter 2025 results call to highlight updated clinical data for its partnered HER2 antibody zanidatamab, outline a new royalty-backed financing with Royalty Pharma, and provide 2025 financial results and pipeline updates across multiple early-stage programs. Partnered zanidatamab program: Phase 3 results and regulatory path Chair, CEO, and interim CFO Ken Galbraith opened by pointing to results from the Phase 3 HERIZON-GEA-01 trial presented at ASCO GI by partners Jazz Pharmaceuticals and BeiGene. In first-line metastatic or locally advanced HER2-positive gastroesophageal adenocarcinoma (GEA), zanidatamab in combination with chemotherapy, with or without a checkpoint inhibitor, demonstrated a median progression-free survival exceeding one year and median overall survival exceeding two years, which Galbraith described as a clinically meaningful outcome in a setting with historically limited long-term survival. ? The H
Show less
Read more
Impact Snapshot
Event Time:
ZYME
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZYME alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZYME alerts
High impacting Zymeworks Inc. news events
Weekly update
A roundup of the hottest topics
ZYME
News
- Zymeworks Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing [Yahoo! Finance]Yahoo! Finance
- Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note FinancingGlobeNewswire
- Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
- Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026GlobeNewswire
ZYME
Earnings
- 3/2/26 - Miss
ZYME
Sec Filings
- 3/2/26 - Form S-8
- 3/2/26 - Form 8-K
- 3/2/26 - Form 10-K
- ZYME's page on the SEC website